



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
	APPLICANT BANKS, ET AL.	
	FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED

### U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE


### FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
		0	8	8	2	7	1	9	12/98	EPO				X
		9	8	5	7	9	3	8	06/98	PCT				X

### OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

1.		H. Arai, et al.; Cloning and expression of a cDNA encoding an Endothelin receptor; Nature; Vol. 348, pp. 730-732 (1990).
2.		A. Tahara, et al.; Circulating Immunoreactive Endothelin in Patients Undergoing Percutaneous Transluminal Coronary Angioplasty; Metab. Clin. Exp.; Vol. 40, pp. 1235-1237 (1991).
3.		S. Douglas, et al.; Endothelin-1 Promotes Neointima Formation After Balloon Angioplasty in the Rat; J. of Cardiovascular Pharm.; 22 (Suppl. 8), 371-373 (1993).
4.		S. Douglas, et al.; A Role for Endogenous Endothelin-1 in Neointimal Formation After Rat Carotid Artery Balloon Angioplasty; Circ. Res.; Vol. 75, pp. 190-197 (1994).
6.		H. Krum, et al.; The effect of an Endothelin-Receptor Antagonist, Bosentan, on Blood Pressure in Patients with Essential Hypertension; New England J. Med.; Vol. 338, pp. 784-790 (1998).
6.		F. E. Strachan, et al.; Systemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men; Hypertension; Vol. 33, p. 581-585 (1999).
7.		Y. Saita, et al.; Mitogenic Activity of Endothelin on Human Cultured Prostatic Smooth Muscle Cells; Eur. J. Pharmacol.; Vol. 349, pp. 123-128 (1988).
8.		R. K. Nikolov, et al.; Cerebrovascular and CNS Effects of Endothelins - Target for Pharmacological Modification; Drugs of Today; Vol. 28(5), 303-310 (1992).
9.		A. E. Benamou, et al.; Variations in Systemic and Pulmonary Endothelin-1 in Horses with Recurrent Airway Obstruction (Heaves); Pulm. Pharm. Ther. Vol. 11, pp. 231-235 (1998).

EXPRESS MAIL NO. EL639818392US



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
		APPLICANT BANKS, ET AL.	
		FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED
10.		A. E. Redington, et al.; Endothelin in Bronchoalveolar Lavage Fluid and Its Relation to Airflow Obstruction in Asthma; Am. J. Resp. Crit. Care Med.; Vol. 151, pp. 1034-1039 (1995).	
11.		K. Tomita, et al.; Molecular analysis of acute renal failure; Med. Philos.; Vol. 13(1), pp. 64-66 (1994).	
12.		F. Stockenhuber, et al.; Plasma levels of Endothelin in Chronic Renal Failure and after renal Transplantation: Impact on hypertension and Cyclosporin A-associated Nephrotoxicity; Clinical Science; Vol. 82, pp. 225-258 (1992).	
13.		M. Yasuda, et al.; Circulating Immunoreactive Endothelin in Ischemic heart Disease; Am. Heart Journal; Vol. 119(4), pp. 801-806 (1990).	
14.		J. T. Stewart, et al.; Plasma Endothelin in Coronary Venous Blood from Patients with Either Stable or Unstable Angina; Br. Heart Journal; Vol. 66, pp. 7-9 (1991).	
15.		D. J. Stewart, et al.; Increased Plasma Endothelin-1 in Pulmonary Hypertension: Marker or Mediator of Disease; Ann. Internal Medicine; Vol. 114, pp. 464-469 (1991).	
15.		R. J. Rodeheffer, et al.; Circulating Plasma Endothelin Correlates with the Severity of Congestive Heart Failure in Humans; Am. Journal of Hypertension; Vol. 4:9A (1991).	
14.		B. A. Clark, et al.; Plasma Endothelin Levels in Preeclampsia: Elevation and Correlation with Uric Acid Levels and Renal Impairment; Am. Journal Obstet. Gynecol.; Vol. 166, pp. 962-969 (1992).	
16.		A. Collier, et al.; Plasma Endothelinlike Immunoreactivity Levels in IDDM Patients with Microalbuminuria; Diabetes Care; Vol. 15(8), pp. 1038-1040 (1992).	
19.		S. H. Murch, et al.; High Endothelin-1 Immunoreactivity in Crohn's Disease and Ulcerative Colitis; Ann. Internal Medicine; Vol. 339, pp. 381-385 (1992).	
20.		A. Lerman, et al.; Circulating and Tissue Endothelin Immunoreactivity in Advanced Atherosclerosis; The New England J. of Medicine; Vol. 325(14), pp. 997-1001 (1991).	
21.		W. J. Jusko, et al.; Plasma and Tissue Protein binding of Drugs in Pharmacokinetics; Drug Metabolism Reviews; Vol. 5(1), pp. 43-140 (1976).	
22.		D. K. Detweiler, et al.; The Prevalence and Types of Cardiovascular Disease in Dogs; Ann. N.Y. Acad. Sci. 481-516.	
23.		R. R. Pensinger; Comparative Aspects of Congestive Heart Failure in Dogs; pp. 335-345 (1986).	
24.		A. Tidholm, et al.; Survival and Prognostic Factors in 189 dogs with Dilated Cardiomyopathy; Journal Am. An. Hosp. Assoc.; Vol. 33, pp. 364-368.	
25.		S. J. Ettinger, et al.; Effects of Enalapril Maleate on Survival of Dogs with Naturally Acquired Heart Failure; JAVMA; Vol. 213 (11), pp. 1573-1577 (1998).	
26.		W. L. Miller, et al.; Integrated Cardiac, Renal, and Endocrine Actions of Endothelin; J. Clin. Invest.; Vol. 83, p. 317-320 (1989).	
27.		R. Pacher, et al.; Prognostic Impact of Big Endothelin-1 Plasma Concentrations Compared With Invasive hemodynamic Evaluation in Severe Heart Failure; JACC; Vol. 27(3); pp. 633-641 (1996).	
28.		G. W. Moe, et al.; Beneficial Effects of long-term Selective Endothelin Type A Receptor Blockade in Canine Experimental Heart Failure; Cardiovascular Research; Vol. 39, pp. 571-579 (1998).	
29.		H. N. Coleman, et al.; Congestive Heart Failure Following Chronic Tachycardia; American Heart Journal; Vol. 81(6), pp. 790-799 (1971).	
30.		G. Hasenfuss; Animal Models of Human Cardiovascular Disease, Heart Failure and Hypertrophy; Cardiovascular Research; Vol. 39, pp. 60-76 (1998).	

2/11/02



INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		ATTY. DOCKET NO. PC10901A	SERIAL NO. 09/779,413
		APPLICANT BANKS, ET AL.	
		FILING DATE FEBRUARY 8, 2001	GROUP NOT YET ASSIGNED
31.		N. Sato, et al.; Mechanisms of Desensitization to a PDE inhibitor (Milrinone) in Conscious Dogs with Heart Failure; Am. Journal Physiol.; Vol. 276, pp. 1699-1705 (1999).	
32.		Sanagi, et al.; Pharmacological profile of YM-598, a novel non-peptide ETA receptor Selective Antagonist; XIIIth International Congress of Pharmacology, Munich, Germany 26-31 (1998).	
EXAMINER  DATE CONSIDERED 2/11/02			
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

Conforms with FORM PTO-FB-A820

INFORMATION DISCLOSURE